Literature DB >> 19652743

Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey.

Josephine Bwogi1, Fiona Braka, Issa Makumbi, Vinod Mishra, Barnabas Bakamutumaho, Miriam Nanyunja, Alex Opio, Robert Downing, Benon Biryahwaho, Rosamund F Lewis.   

Abstract

BACKGROUND: Infant immunization against hepatitis B began in Uganda in 2002.
OBJECTIVE: To determine the baseline prevalence of hepatitis B virus (HBV) infection and explore risk factors.
METHODS: A hepatitis B prevalence study was nested in the 2005 national HIV/AIDS serobehavioural survey. Demographic characteristics and risk factors were explored by questionnaire. One third of blood specimens (n=5875) from adults aged 15 to 59 years were tested for hepatitis B core antibodies (HBcAb); positive specimens were tested for hepatitis B surface antigen (HBsAg).
RESULTS: HBcAb was present in 52.3% (95% CI: 51.0-53.6) of adults, and HBsAg in 10.3% (9.5-11.1). By 15-19 years of age, 40.0% had been infected with HBV. Prevalence of both markers was significantly higher across northern Uganda, in rural areas, among the poor and least educated, and in uncircumcised men. Other independent predictors of infection were age, ethnic group, occupation, number of sex partners, and HIV and HSV-2 status.
CONCLUSION: Hepatitis B virus infection is highly endemic in Uganda, with transmission occurring in childhood and adulthood. More than 1.4 million adults are chronically infected and some communities disproportionately affected. The hepatitis B infant immunization programme should be sustained and catch-up vaccination considered for older children.

Entities:  

Keywords:  HBcAb; HBsAg; HIV; Hepatitis B is highly endemic in Uganda; Uganda; circumcision; coinfection; hepatitis B; immunization; survey; vaccine

Mesh:

Substances:

Year:  2009        PMID: 19652743      PMCID: PMC2707048     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  29 in total

Review 1.  Unsafe injections in the developing world and transmission of bloodborne pathogens: a review.

Authors:  L Simonsen; A Kane; J Lloyd; M Zaffran; M Kane
Journal:  Bull World Health Organ       Date:  1999       Impact factor: 9.408

2.  Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa.

Authors:  Donatus U Ekwueme; Bruce G Weniger; Robert T Chen
Journal:  Bull World Health Organ       Date:  2002-12-03       Impact factor: 9.408

3.  Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS.

Authors:  S Vento; G di Perri; R Luzzati; M Cruciani; T Garofano; C Mengoli; E Concia; D Bassetti
Journal:  Lancet       Date:  1989-02-11       Impact factor: 79.321

4.  Hepatitis B virus and hiv infections among patients in Mulago hospital.

Authors:  F N Nakwagala; M M Kagimu
Journal:  East Afr Med J       Date:  2002-02

5.  Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Andrea Kovacs; Peter Bacchetti; Audrey L French; Michael Augenbraun; Stephen R Cole; Nancy Hessol; Jessica Justman
Journal:  Clin Infect Dis       Date:  2004-10-07       Impact factor: 9.079

Review 6.  Global control of hepatitis B virus infection.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Lancet Infect Dis       Date:  2002-07       Impact factor: 25.071

7.  Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients.

Authors:  R N Gunson; D Shouval; M Roggendorf; H Zaaijer; H Nicholas; H Holzmann; A de Schryver; D Reynders; J Connell; W H Gerlich; R T Marinho; D Tsantoulas; E Rigopoulou; M Rosenheim; D Valla; V Puro; J Struwe; R Tedder; C Aitken; M Alter; S W Schalm; W F Carman
Journal:  J Clin Virol       Date:  2003-08       Impact factor: 3.168

8.  Risk factors for the spread of AIDS in rural Africa: evidence from a comparative seroepidemiological survey of AIDS, hepatitis B and syphilis in southwestern Uganda.

Authors:  C P Hudson; A J Hennis; P Kataaha; G Lloyd; A T Moore; G M Sutehall; R Whetstone; T Wreghitt; A Karpas
Journal:  AIDS       Date:  1988-08       Impact factor: 4.177

9.  Hepatitis B virus reactivation or reinfection associated with HIV-1 infection.

Authors:  J Waite; R J Gilson; I V Weller; C J Lacey; M H Hambling; A Hawkins; M Briggs; R S Tedder
Journal:  AIDS       Date:  1988-12       Impact factor: 4.177

10.  Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials.

Authors:  Leigh Anne Eller; Michael A Eller; Benson Ouma; Peter Kataaha; Denis Kyabaggu; Richard Tumusiime; Joseph Wandege; Ronald Sanya; Warren B Sateren; Fred Wabwire-Mangen; Hannah Kibuuka; Merlin L Robb; Nelson L Michael; Mark S de Souza
Journal:  PLoS One       Date:  2008-12-11       Impact factor: 3.240

View more
  52 in total

1.  Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana.

Authors:  Premal Patel; Stephanie Davis; Michael Tolle; Vincent Mabikwa; Gabriel Anabwani
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

2.  Prevalence of Hepatitis B Virus Infection in Kenya, 2007.

Authors:  Kathleen N Ly; Andrea A Kim; Mamo Umuro; Jan Drobenuic; John M Williamson; Joel M Montgomery; Barry S Fields; Eyasu H Teshale
Journal:  Am J Trop Med Hyg       Date:  2016-06-06       Impact factor: 2.345

3.  Hepatitis B incidence and prevention with antiretroviral therapy among HIV-positive individuals in Uganda.

Authors:  Emmanuel Seremba; Victor Ssempijja; Sarah Kalibbala; Ronald H Gray; Maria J Wawer; Fred Nalugoda; Corey Casper; Warren Phipps; Ponsiano Ocama; David Serwadda; David L Thomas; Steven J Reynolds
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

4.  Hepatitis B virus and sexual behavior in Rakai, Uganda.

Authors:  Lara Stabinski; Steven J Reynolds; Ponsiano Ocama; Oliver Laeyendecker; David Serwadda; Ron H Gray; Maria Wawer; David L Thomas; Thomas C Quinn; Gregory D Kirk
Journal:  J Med Virol       Date:  2011-05       Impact factor: 2.327

5.  Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda.

Authors:  Joy Baseke; Monica Musenero; Harriet Mayanja-Kizza
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

6.  Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.

Authors:  Ponsiano Ocama; Emmanuel Seremba; Betty Apica; Kenneth Opio
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

7.  Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda.

Authors:  E Seremba; J P Van Geertruyden; R Ssenyonga; C K Opio; J M Kaducu; J B Sempa; R Colebunders; P Ocama
Journal:  Vaccine       Date:  2017-04-20       Impact factor: 3.641

8.  Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey.

Authors:  Adebola T Olayinka; Akin Oyemakinde; Muhammad S Balogun; Anthonia Ajudua; Patrick Nguku; Moses Aderinola; Abiodun Egwuenu-Oladejo; Simeon W Ajisegiri; Samuel Sha'aibu; Bolanle O P Musa; Saheed Gidado; Abdulsalami Nasidi
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

9.  Decompensated cirrhosis-related admissions in a large urban hospital in Uganda: prevalence, clinical and laboratory features and implications for planning patient management.

Authors:  B S Apica; P Ocama; E Seremba; K C Opio; M M Kagimu
Journal:  Afr Health Sci       Date:  2013-12       Impact factor: 0.927

10.  Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya.

Authors:  Elizabeth Irungu; Nelly Mugo; Kenneth Ngure; Robert Njuguna; Connie Celum; Carey Farquhar; Shireesha Dhanireddy; Jared M Baeten
Journal:  J Infect Dis       Date:  2012-11-21       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.